PCV11 EVALUATING CLINICAL OUTCOMES FOR SUBJECTS THAT ARE NEWLY INITIATED ON HMG-COA REDUCTASE INHIBITORS IN A NATURALISTIC ENVIRONMENT USING LONGITUDINAL DESIGN  by Al-Zakwani, I et al.
321Abstracts
monitoring started from 1 July 2001. The primary outcome mea-
surement was the LDL levels. The secondary outcome measure-
ment was the percentage of goal attainment. Lipid control was
deﬁned as adequate if the LDL level was < or = 2.6mmol/L. The
LDL levels were measured at baseline, 1, 3, 6, and 12 months.
RESULTS: A total of 617 patients were recruited. There were
383 patients in the intensive monitoring group and 283 patients
in the control group. In the control group, a less intensive mon-
itoring was adopted. Less than 20% of control group patients
had a regular 3-monthly LDL-levels monitoring. Over 60% of
patients in the intensive monitoring group and 10% of the
control group patients reached target LDL-levels by week 4.
Over 90% of the intensive monitoring group patients maintained
at target LDL levels in a following 6-month period. CONCLU-
SION: This study shows that intensive monitoring of LDL-levels
in hyperlipidaemic patients receiving PCI have a higher goal
attainment rate that remains high within 6-month period. This
study paves way for a prospective, randomized-control trial to
conﬁrm the results in the future.
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OBJECTIVES: To evaluate lipid level changes, NCEP-ATPIII
LDL-C goal attainment and time to goal in a managed care
setting. METHODS: Patients were included if they began ator-
vastatin, ﬂuvastatin, pravastatin, or simvastatin therapy between
July 1, 1999 and June 30, 2001, and had no dyslipidemic therapy
in the previous 6 months, continuous health plan enrollment, 6
months pre-index and 12 months post-index, and post-index
lipid measurements. Goal attainment status was assessed at each
LDL-C lab result utilizing NCEP-ATPIII guidelines. Descriptive
statistics, generalized estimating equations (GEE), and Cox 
proportional hazard with multiple-failure data were employed
for analysis. Model covariates included age, gender, coronary
artery disease, diabetes mellitus, hypertension, duration of statin
therapy, medication possession ratio (MPR), and baseline lipid
proﬁle. RESULTS: A total of 16,979 patients were identiﬁed for
this study (ﬂuvastatin = 1251; pravastatin = 2302; simvastatin =
5603; atorvastatin = 7823). The mean overall age of the cohort
was 62 ± 13 years, 49% were male, and 58% of patients were
deﬁned as secondary prevention by NCEP-ATPIII risk criteria.
The overall mean duration of therapy (persistence) was 16 ± 9
months and adherence to therapy (MPR) was 79%. The
mean/median doses were as follows: atorvastatin = 14mg/10mg,
ﬂuvastatin = 35mg/40mg, pravastatin = 28mg/20mg and sim-
vastatin = 24mg/20mg. Changes in lipid levels for atorvastatin,
ﬂuvastatin, pravastatin, and simvastatin were as follows: total
cholesterol (-21%, -15%, -16%, -20%), LDL-C (-28%, 
-21%, -23%, -28%), HDL-C (0.1%, 1.0%, 1.0%, 1.5%), 
and triglycerides (-8%, -1%, -3%, -5%), respectively. The
probabilities of achieving LDL-C goal and median times to 
goal were: atorvastatin (0.51, 236 days); ﬂuvastatin (0.30, 379
days); pravastatin (0.35, 377 days); simvastatin (0.47, 246 
days). CONCLUSIONS: Patients who were prescribed atorvas-
tatin had signiﬁcantly greater improvements in total cholesterol
and triglycerides and attained LDL-C goal signiﬁcantly more
often evaluating each lab result independently. Changes in 
LDL-C and HDL-C were similar between atorvastatin and 
simvastatin.
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OBJECTIVE: Angiotension II receptor antagonists (ARB)
provide a new therapeutic option for hypertensive patients. This
analysis examines patient utilization patterns subsequent to ini-
tiation on an ARBs. METHODS: This study uses a retrospective
cohort design with a six-month baseline period and a twelve-
month evaluation period. New users of ARBs were identiﬁed in
AdvancePCS¢ pharmacy claims database. Studied patients were
continuously eligible for pharmacy beneﬁts, 20 to 80 years of
age, and initiated therapy on losartan, valsartan, ibersartan, can-
desartan, telmisartan, losartan HCT, valsartan HCT, candesar-
tan HCT, or telmisartan HCT between November 1, 2001 and
April 30, 2002. RESULTS: A total of 167,083 patients initiated
ARB therapy during the enrollment window, 72% on ARB
monotherapy and 28% on combination therapy. Monotherapy
patients (p < 0.05) were more likely to discontinue than combi-
nation therapy patients. No other signiﬁcant differences in 
discontinuation rates were identiﬁed. Patients who initiated with
monotherapy were equally likely to add a diuretic as a second
therapy regardless of ARB. Patients who initiated on telmisartan
were less likely (p < 0.05) than patients who initiated on losar-
tan (OR = 0.67), valsartan (OR = 0.81), ibersartan (OR = 0.82),
or candesartan (OR = 0.82) to receive triple anti-hypertensive
therapy. Similarly, patients who initiated on valsartan (OR =
1.23) or losartan monotherapy (OR = 1.14) were more likely
than other monotherapy patients (p < 0.05) to titrate upwards.
Combination patients who initiated on losartan HCT or valsar-
tan HCT were more likely to add another anti-hypertensive drug
than were patients who initiated on either candesartan HCT (OR
= 0.69, p < 0.05) or telmisartan HCT (OR = 0.82, p < 0.05).
Those who initiated telmisartan HCT were least likely to
increase the initial dose (p < 0.05). CONCLUSIONS: Differences
in patient utilization patterns were identiﬁed based on initial
choice of ARB. These ﬁndings may result from differential clin-
ical efﬁcacy, patient health history, or managed care inﬂuence on
drug choice.
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OBJECTIVES: Carotid artery stenosis is an important risk factor
for, and is also believed to cause as much as 20% all strokes.
Several surgical therapies are available including carotid
endarterectomy (CEA) and carotid angioplasty with stenting
(CAS). Although there appear to be beneﬁts to adopting wide-
spread use of CAS, numerous parties have expressed concern
about its safety. A number of large protected CAS (PCAS) trials
are underway, however, it will be 3 to 5 years until these results
are released. In the interim, PCAS continues to be employed.
Since numerous PCAS studies were recently published, the aim
of this systematic review was to answer the question: based on
the most recent evidence, what is the efﬁcacy of protected carotid
angioplasty with stenting (PCAS)? METHODS: Electronic,
manual and bibliographic searches of Medline, PreMedline,
Healthstar/OVID, EMBase, PubMed were conducted.
RESULTS: Over 400 articles were identiﬁed, of which 18 studies
met the inclusion criteria. The technical complication rate of
